Clinical trials recruiting for Solid Tumor, Adult
38
Recruiting trials
30
US states with sites
15
Countries
3%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 19 |
| Florida | 19 |
| Texas | 18 |
| New York | 14 |
| Tennessee | 13 |
| Massachusetts | 10 |
| Pennsylvania | 9 |
| Colorado | 8 |
| Missouri | 8 |
| Virginia | 8 |
| Arizona | 7 |
| Michigan | 7 |
Top cities
Houston, Texas 15New York, New York 14Nashville, Tennessee 12Boston, Massachusetts 10Los Angeles, California 10Dallas, Texas 8Fairfax, Virginia 8San Francisco, California 8St Louis, Missouri 8Seattle, Washington 7
Self-screener
Recruiting trials
- 64Cu-GRIP B in Patients With Advanced Malignancies
- A Beta-only IL-2 ImmunoTherapY Study
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of VET3-TGI in Patients With Solid Tumors
- A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
- A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- COAST Therapy in Advanced Solid Tumors and Prostate Cancer
- DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer
- Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
- Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
- Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- GPC3/Mesothelin-CAR-γδT Cells Against Cancers
- Interventional Software for Multi-immunotherapy of Solid Tumors
- Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
- Intravital Microscopy in Human Solid Tumors
- Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- PRE-ISPY Phase I/II Oncology Platform Program
- Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
- Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
- Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
- TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
- Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Related conditions
Trials recruiting for Solid Tumor, Adult often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Colorectal cancer 1359Pancreatic cancer 870Breast cancer 2239Non-small cell lung cancer 507Melanoma 487Triple-negative breast cancer 138Ovarian cancer 118Gastric cancer 91Pancreas Cancer 86
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Solid Tumor, Adult trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.